Sanofi Holds Brainstorming Sessions To Fuel Its Therapeutic Strategy Units
This article was originally published in Pharmaceutical Approvals Monthly
Just two years after Sanofi-Aventis SA set out to reinvent itself as the flexible, entrepreneurial, easy-partnering, globally diversified health care leader of the future, the French pharma has mounted a grassroots campaign to familiarize the academic/biotech community with its new Therapeutic Strategy Units, a handful of targeted areas with high unmet need and commensurately huge opportunity that are part of Sanofi's long-range R&D strategy.
You may also be interested in...
In two very different collaborations, Sanofi teams up with Weill Cornell professor to screen for TB drug candidates, while UCB initiates its first project under a strategic research alliance with Harvard.
Pfizer's ambitious tie-ups with multiple research institutions across several cities is but the latest model of academic-industry collaboration, highlighting pharma's ongoing hunger for fresh approaches to drug discovery.
At the forefront of radical R&D reorganization, GlaxoSmithKline continues to evolve its model, characterized to date by the breaking up of R&D into small, biotech-like drug performance units (DPUs). These units are about to undergo the latest round of change: closer integration with the downstream medicines development centers in their respective therapeutic areas. The move makes sense given industry's growing recognition of the need for payor and regulator requirements to inform even early-stage discovery and development.